专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06855722B2 Substituted indoles and their use as integrin antagonists 有权
标题翻译：取代的吲哚及其作为整联蛋白拮抗剂的用途
公开(公告)号：US06855722B2
公开(公告)日：2005-02-15
申请号：US10058215
申请日：2002-01-29
申请人： Tianbo Lu , Louis V. LaFrance , Thomas P. Markotan , Juan J. Marugan Sanchez , Victor J. Marder , David C. U'Prichard , Beth M. Anaclerio , Zihong Guo , Wenzi Pan , Kristi A. Leonard , Bruce E. Tomczuk
发明人： Tianbo Lu , Louis V. LaFrance , Thomas P. Markotan , Juan J. Marugan Sanchez , Victor J. Marder , David C. U'Prichard , Beth M. Anaclerio , Zihong Guo , Wenzi Pan , Kristi A. Leonard , Bruce E. Tomczuk
IPC分类号： A61K31/404 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/5383 , A61P3/06 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/22 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D213/74 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D498/04
CPC分类号： C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要： The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译：本发明涉及作为αV（alphav）整联蛋白的拮抗剂的新型取代的吲哚化合物，例如阿尔法博3和阿尔法肽5整联蛋白，其药学上可接受的盐及其药物组合物。这些化合物可以用于治疗由α1和α2融合蛋白介导的病理状态，包括肿瘤生长，转移，再狭窄，骨质疏松症，炎症，黄斑变性，糖尿病性视网膜病变和类风湿性关节炎等病症。化合物具有以下通式：其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8， R 9，R 10，R 11，R 12，R 13，R 14，D，X，W，a，m，n，i，j，k和v 。

2. 发明授权

US07241789B2 Substituted indoles and their use as integrin antagonists 有权
标题翻译：取代的吲哚及其作为整联蛋白拮抗剂的用途
公开(公告)号：US07241789B2
公开(公告)日：2007-07-10
申请号：US11005294
申请日：2004-12-06
申请人： Tianbo Lu , Bruce E. Tomczuk , Louis V. LaFrance , Thomas P. Markotan , Juan J. Marugan Sanchez , Victor J. Marder , David C. U'Prichard , Beth M. Anaclerio , Zihong Guo , Wenzi Pan , Kristi A. Leonard
发明人： Tianbo Lu , Bruce E. Tomczuk , Louis V. LaFrance , Thomas P. Markotan , Juan J. Marugan Sanchez , Victor J. Marder , David C. U'Prichard , Beth M. Anaclerio , Zihong Guo , Wenzi Pan , Kristi A. Leonard
IPC分类号： C07D471/04 , C07D498/04 , A61K31/404 , A61P25/18
CPC分类号： C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要： The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译：本发明涉及作为αV（alphav）整联蛋白的拮抗剂的新的取代的吲哚化合物，例如α缬氨酸和/ β5整联蛋白，其药学上可接受的盐及其药物组合物。该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。整合素，包括肿瘤生长，转移，再狭窄，骨质疏松症，炎症，黄斑变性，糖尿病性视网膜病变和类风湿性关节炎等病症。化合物具有以下通式：其中R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，R 8，R 9，R 9， D 10，R 11，R 12，R 13，R 14，D， X，W，a，m，n，i，j，k和v在本文中定义。

3. 发明申请

US20070219233A1 Substituted Indoles and Their Use as Integrin Antagonists 审中-公开
标题翻译：取代的吲哚及其作为整合素拮抗剂的用途
公开(公告)号：US20070219233A1
公开(公告)日：2007-09-20
申请号：US11755831
申请日：2007-05-31
申请人： Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人： Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号： A61K31/4353 , C07D471/04
CPC分类号： C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要： The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译：本发明涉及作为αV（alphav）整联蛋白的拮抗剂的新的取代的吲哚化合物，例如α缬氨酸和/ β5整联蛋白，其药学上可接受的盐及其药物组合物。该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。整合素，包括肿瘤生长，转移，再狭窄，骨质疏松症，炎症，黄斑变性，糖尿病性视网膜病变和类风湿性关节炎等病症。化合物具有以下通式：其中R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，R 8，R 9，R 9， D 10，R 11，R 12，R 13，R 14，D， X，W，a，m，n，i，j，k和v在本文中定义。

4. 发明申请

US20050250771A1 Substituted indoles and their use as integrin antagonists 有权
标题翻译：取代的吲哚及其作为整联蛋白拮抗剂的用途
公开(公告)号：US20050250771A1
公开(公告)日：2005-11-10
申请号：US11005294
申请日：2004-12-06
申请人： Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人： Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号： A61K31/404 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/5383 , A61P3/06 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/22 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D213/74 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D498/04 , A61K31/538 , A61K31/405 , A61K31/4745 , A61K31/506 , C07D413/02 , C07D43/02
CPC分类号： C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要： The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, , R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译：本发明涉及作为αV（alphav）整联蛋白拮抗剂的新型取代的吲哚化合物，例如阿尔茨海默氏症和/ 整联蛋白，其药学上可接受的盐及其药物组合物。该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。整合素，包括肿瘤生长，转移，再狭窄，骨质疏松症，炎症，黄斑变性，糖尿病性视网膜病变和类风湿性关节炎等病症。化合物具有以下通式：其中R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，R 8，R 9，R 9， R 10，R 11，R 12，R 12，R 14，D 12，，X，W，a，m，n，i，j，k和v在本文中定义。

5. 发明申请

US20050209225A1 Substituted indoles and their use as integrin antagonists 审中-公开
标题翻译：取代的吲哚及其作为整联蛋白拮抗剂的用途
公开(公告)号：US20050209225A1
公开(公告)日：2005-09-22
申请号：US11005596
申请日：2004-12-06
申请人： Tianbao Lu , Louis LaFrance , Bruce Tomczuk , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人： Tianbao Lu , Louis LaFrance , Bruce Tomczuk , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号： A61K31/404 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/5383 , A61P3/06 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/22 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D213/74 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D498/04 , A61K31/538 , A61K31/405 , A61K31/4745 , A61K31/506
CPC分类号： C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要： The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译：本发明涉及作为αV（alphav）整联蛋白的拮抗剂的新的取代的吲哚化合物，例如α缬氨酸和/ β5整联蛋白，其药学上可接受的盐及其药物组合物。该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。整合素，包括肿瘤生长，转移，再狭窄，骨质疏松症，炎症，黄斑变性，糖尿病性视网膜病变和类风湿性关节炎等病症。化合物具有以下通式：其中R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，R 8，R 9，R 9， D 10，R 11，R 12，R 13，R 14，D， X，W，a，m，n，i，j，k和v在本文中定义。

6. 外观设计

USD983895S1 Coffee maker toy 有权
公开(公告)号：USD983895S1
公开(公告)日：2023-04-18
申请号：US29841115
申请日：2022-06-02
申请人： Zihong Guo
设计人： Zihong Guo

7. 发明授权

US09205969B2 Temperature-stabilized storage systems 有权
标题翻译：温度稳定的存储系统
公开(公告)号：US09205969B2
公开(公告)日：2015-12-08
申请号：US12658579
申请日：2010-02-08
申请人： Geoffrey F. Deane , Lawrence Morgan Fowler , William Gates , Zihong Guo , Roderick A. Hyde , Edward K. Y. Jung , Jordin T. Kare , Nathan P. Myhrvold , Nathan Pegram , Nels R. Peterson , Clarence T. Tegreene , Charles Whitmer , Lowell L. Wood, Jr.
发明人： Geoffrey F. Deane , Lawrence Morgan Fowler , William Gates , Zihong Guo , Roderick A. Hyde , Edward K. Y. Jung , Jordin T. Kare , Nathan P. Myhrvold , Nathan Pegram , Nels R. Peterson , Clarence T. Tegreene , Charles Whitmer , Lowell L. Wood, Jr.
IPC分类号： B65D81/38 , B65G1/127 , B01L9/06
CPC分类号： B65D81/3802 , B65D81/3811 , B65D81/3813 , B65D81/3823 , B65D81/3825 , B65D81/3834 , B65D81/3888 , B65D81/3897 , B65D2203/10 , Y10T29/49826
摘要： A substantially thermally sealed storage container includes an outer assembly, including one or more sections of ultra efficient insulation material substantially defining at least one thermally sealed storage region, and an inner assembly, including at least one heat sink unit within the at least one thermally sealed storage region, and at least one stored material dispenser unit, wherein the at least one stored material dispenser unit includes one or more interlocks.
摘要翻译：基本上热密封的存储容器包括外部组件，其包括基本上限定至少一个热密封存储区域的一个或多个超高效绝缘材料部分和内部组件，所述内部组件包括至少一个热密封的至少一个散热器单元存储区域和至少一个储存材料分配器单元，其中所述至少一个储存的材料分配器单元包括一个或多个互锁。

8. 发明授权

US08235975B2 Light transmission system for photoreactive therapy 有权
标题翻译：用于光反应治疗的光传输系统
公开(公告)号：US08235975B2
公开(公告)日：2012-08-07
申请号：US13274192
申请日：2011-10-14
申请人： James C. Chen , Steven R. Daly , Zihong Guo , Llew Keltner , Jeffrey R. Storm
发明人： James C. Chen , Steven R. Daly , Zihong Guo , Llew Keltner , Jeffrey R. Storm
IPC分类号： A61B18/18
CPC分类号： A61N5/062 , A61B50/30 , A61N5/0601 , A61N2005/0645 , A61N2005/0652
摘要： A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.
摘要翻译：向患者提供光动力治疗的光传输系统包括具有多个发光二极管（LED）的单次使用的集成控制模块和导管组件，以将光传送到患者体内的靶细胞。集成光导管和控制模块与光活化药物组合使用。所选择的操作参数可以被编程到控制模块中，或者可以在使用之前在现场进行无线可编程，以允许用户灵活地为特定患者或病症定制治疗。防止重用的功能之一是控制模块缺少对电源进行再充电的功能，并且可能包括在触发时破坏电路或软件的停用模块。为了在使用时防止患者干扰，控制模块还可以被配置为选择性地停用。

9. 发明申请

US20120089207A1 LIGHT TRANSMISSION SYSTEM FOR PHOTOREACTIVE THERAPY 有权
标题翻译：用于光敏治疗的光传输系统
公开(公告)号：US20120089207A1
公开(公告)日：2012-04-12
申请号：US13274192
申请日：2011-10-14
申请人： James C. Chen , Steven R. Daly , Zihong Guo , Llew Keltner , Jeffrey R. Storm
发明人： James C. Chen , Steven R. Daly , Zihong Guo , Llew Keltner , Jeffrey R. Storm
IPC分类号： A61N5/06
CPC分类号： A61N5/062 , A61B50/30 , A61N5/0601 , A61N2005/0645 , A61N2005/0652
摘要： A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.
摘要翻译：向患者提供光动力治疗的光传输系统包括具有多个发光二极管（LED）的单次使用的集成控制模块和导管组件，以将光传送到患者体内的靶细胞。集成光导管和控制模块与光活化药物组合使用。所选择的操作参数可以被编程到控制模块中，或者可以在使用之前在现场进行无线可编程，以允许用户灵活地为特定患者或病症定制治疗。防止重用的功能之一是控制模块缺少对电源进行再充电的功能，并且可能包括在触发时破坏电路或软件的停用模块。为了在使用时防止患者干扰，控制模块还可以被配置为选择性地停用。

10. 发明申请

US20090036773A1 METHODS AND APPARATUS FOR ENGAGEMENT AND COUPLING OF AN INTRACAVITORY IMAGING AND HIGH INTENSITY FOCUSED ULTRASOUND PROBE 有权
标题翻译：入侵和联合成像和高强度聚焦超声探头的方法和装置
公开(公告)号：US20090036773A1
公开(公告)日：2009-02-05
申请号：US11831048
申请日：2007-07-31
申请人： Michael P. H. Lau , Gregory Paul Darlington , Michael J. Connolly , Zihong Guo
发明人： Michael P. H. Lau , Gregory Paul Darlington , Michael J. Connolly , Zihong Guo
IPC分类号： A61B8/12 , A61N7/00
CPC分类号： A61B8/12 , A61B8/4209 , A61B8/4272 , A61B8/4281 , A61B8/445 , A61B17/2202 , A61B17/2256 , A61B17/4241 , A61B2017/2253 , A61B2017/4216 , A61B2018/00029 , A61B2090/3782 , A61B2090/3784 , A61N7/022
摘要： A combined imaging/HIFU probe includes an imaging scan head, a HIFU transducer, and an outlet port that delivers a flow of fluid across the HIFU transducer. At least a portion of the body cavity is filled with fluid in which the probe is immersed. The fluid provides a coupling for transmission of ultrasound energy between the probe and the patient. A flow of fluid may also be used to flush obstructions from an area of tissue near the HIFU transducer. Further described herein is a cuff to help retain fluid in the body cavity, a regulator to regulate fluid flow with respect to the body cavity according to a desired fluid pressure, and a cover for the HIFU transducer that has at least one perforation defined therethrough to allow fluid to flow through the cover. Further disclosed herein are methods of deploying a combined imaging/HIFU probe in a body cavity.
摘要翻译：组合的成像/ HIFU探头包括成像扫描头，HIFU换能器和输出流体穿过HIFU换能器的出口。体腔的至少一部分填充有探针浸入其中的流体。流体提供用于在探针和患者之间传输超声能量的耦合。流体流也可用于冲洗HIFU换能器附近的组织区域的障碍物。本文进一步描述的是用于帮助保持体腔中的流体的袖带，根据期望的流体压力调节流体相对于体腔的流体的调节器，以及用于HIFU换能器的覆盖物，其具有至少一个穿过其定义的穿孔允许流体流过盖子。本文进一步公开的是将组合成像/ HIFU探针部署在体腔中的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式